Radient Pharmaceuticals Monetizing China-Based Jade Pharmaceutical Division

US-based pharmaceutical company Radient Pharmaceuticals Corporation (RPC) (AMEX:RPC ) announced today it anticipates prospective purchasers or financiers will complete due diligence for RPC's China-based subsidiary Jade Pharmaceutical, Inc. ("JPI") by the end of May 2010.

RPC expects JPI will be contractually positioned to move forward with the completion of a sale or financing by the end of the third quarter 2010. RPC currently owns approximately 98% of JPI, which as part of RPC's deconsolidation process, is noted as a special asset on RPC's balance sheet and valued at approximately US$20 million as of September 30, 2009.

According to Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals Corporation, "We are extremely pleased to move down an orderly path to maximize the monetization of our China-based asset. This is in accordance with our original deconsolidation plan and is in the best interest of the company, our subsidiary and RPC shareholders."

For additional information on Radient Pharmaceuticals or JPI visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Ms. Kristine Szarkowitz at This email address is being protected from spambots. You need JavaScript enabled to view it. or 1.206.310.5323 begin_of_the_skype_highlighting              1.206.310.5323      end_of_the_skype_highlighting.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact:

 
AMDL Contact: 
Kristine Szarkowitz 
Director-Investor Relations 
Email Contact
(Tel: ) 206.310.5323 begin_of_the_skype_highlighting              206.310.5323      end_of_the_skype_highlighting